Chimeric Antigen Receptor T Cells (CAR T-Cells): A New Frontier in Targeted Cancer Therapy
Bibliographic record
Abstract
Introduction and Definition: The conventional approaches to cancer treatment—surgery, chemotherapy, and radiation therapy—while effective, often come with significant side effects and limitations, especially in advanced or metastatic disease. This has led to the rise of immunotherapy, a revolutionary approach that leverages the body's immune system to recognize and eliminate cancer cells. Among immunotherapies, Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a ground breaking treatment. This therapy involves genetically modifying a patient's own T cells, key components of the adaptive immune response, to specifically target and destroy cancer cells. As a form of personalized medicine, CAR T-cell therapy is transforming cancer treatment by offering a novel, highly targeted strategy, particularly effective in certain hematologic malignancies. It represents a convergence of immunology and genetic engineering, creating T cells that act as potent cancer-killing agents. CAR T-cell therapy modifies T cells in the lab so they can find and destroy cancer cells, effectively turning a patient's T lymphocytes into cancer-fighting machines. Body: The origins of CAR T-cell therapy trace back over six decades to the exploration of adoptive cell transfer (ACT). Early research focused on utilizing the anti-tumor potential of lymphocytes in animal models. However, a significant obstacle was overcoming the body's natural tolerance to self-antigens, which prevents immune responses against cancer cells that resemble healthy tissues. Advances in genetic engineering have since enabled the modification of T cells to recognize and attack cancer cells effectively. This breakthrough has overcome previous challenges and paved the way for CAR T-cell therapy's clinical success, offering new hope in the fight against cancer.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.002 |
| Scholarly communication | 0.002 | 0.003 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.003 | 0.005 |
| Insufficient payload (model declined to judge) | 0.003 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".